Post-Interleukin 17
K |
|||
| (6 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA Biologicals}} | ||
| + | ---- | ||
| + | secukinumab, ixekizumab, brodalumab | ||
| + | ---- | ||
| + | |||
{{tp|p=32353597|t=ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy |pdf=|usr=}} | {{tp|p=32353597|t=ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy |pdf=|usr=}} | ||
{{tp|p=32358580|t=ä. COVID-19: a case for inhibiting IL-17?|pdf=|usr=}} | {{tp|p=32358580|t=ä. COVID-19: a case for inhibiting IL-17?|pdf=|usr=}} | ||
{{tp|p=32302707|t=ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak |pdf=|usr=}} '''frisch geboren und schon publiziert...''' | {{tp|p=32302707|t=ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak |pdf=|usr=}} '''frisch geboren und schon publiziert...''' | ||
| + | {{tp|p=32339777|t=2020. May IL-17 have a role in COVID-19 infection?|pdf=|usr=}} | ||
| + | {{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32475041|t=2020. Potential role of Anti-IL-17 in COVID-19 treatment.|pdf=|usr=007}} | ||
| + | {{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=009}} | ||
| + | {{tp|p=32557955|t=2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.|pdf=|usr=010}} | ||
| + | {{tp|p=32627226|t=2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?|pdf=|usr=012}} | ||
| + | {{tp|p=32651218|t=2020. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.|pdf=|usr=014}} | ||
Aktuelle Version vom 12. April 2021, 15:22 Uhr
| PHA Biologicals |
secukinumab, ixekizumab, brodalumab
32353597 ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy
32358580 ä. COVID-19: a case for inhibiting IL-17?
32302707 ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak frisch geboren und schon publiziert...
32339777 2020. May IL-17 have a role in COVID-19 infection?
32504739 2020. Interleukin-17: A potential therapeutic target in COVID-19.
32475041 2020. Potential role of Anti-IL-17 in COVID-19 treatment.
32445955 2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"
32557955 2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.
32627226 2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?
32651218 2020. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.
